Tag
A prespecified subanalysis of the PACMAN-HF trial demonstrates that individualized nutritional interventions in chronic heart failure patients at risk of malnutrition improve nutritional status and functional capacity but do not significant
This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFp
Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.
In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF i
This study identifies key Fontan circulatory failure morbidities impacting survival from heart transplant waitlisting through one year post-transplant, highlighting cyanosis and frequent hospitalizations as critical risk factors.
The DANFLU-2 trial reveals that high-dose influenza vaccine significantly reduces hospitalization for influenza and cardiovascular events in older adults, including those with heart failure, compared to the standard-dose vaccine.
The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.
Cardiac MRI T1 mapping and extracellular volume fraction (ECV) provide noninvasive markers of myocardial fibrosis, showing consistent prognostic value across heart failure subtypes and non-ischaemic dilated cardiomyopathy for adverse cardio
The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer
Bayesian modelling of combined systolic and diastolic function trajectories in older adults reveals distinct patterns predicting heart failure subtypes and identifies potential proteomic targets for therapy.
This study integrates longitudinal systolic and diastolic cardiac function measures using Bayesian modeling to identify trajectories associated with distinct heart failure subtypes and proteomic signatures, enhancing risk prediction and the
Mobile app-assisted screening in primary care settings identified new heart failure cases in one-third of at-risk patients, especially those with preserved ejection fraction, highlighting a promising route for early diagnosis.
Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.
The DIGIT-HF trial sheds new light on digitoxin’s role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.
The DIGIT-HF trial reveals that adding low-dose digitoxin to standard heart failure treatment reduces hospitalization and all-cause mortality in symptomatic HFrEF patients, highlighting a potential resurgence for this historic cardiac glyco
Heart failure is a serious but manageable condition. Recognizing early symptoms and understanding risk factors can save lives. Here’s a comprehensive guide on prevention, diagnosis, and management for both the public and health professional
Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.
A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.
This study explores the Left Atrial Coupling Index as a key predictor in heart failure patients with preserved ejection fraction.
Withdrawal of renin-angiotensin inhibitors and mineralocorticoid receptor antagonists in patients with heart failure and improved ejection fraction significantly increases 1-year cardiovascular mortality and hospitalization risks; beta-bloc
